| Symbol | ENZC |
|---|---|
| Name | ENZOLYTICS INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 75013 United States TX 1101 RAINTREE CIRCLE STE 130 |
| Telephone | +1 4698031287 |
| Fax | — |
| — | |
| Website | http://www.enzolytics.com |
| Incorporation | US |
| Incorporated On | 2007 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Mallett & Barnes Tax Service;Fruci & Associates II, PLLC; |
| Audit Status | UNAUDITED |
| Reporting Status | Alternative Reporting Standard |
| CIK | 0001421851 |
| Description | Business Description Enzolytics, Inc. (the "Company" or "ENZC") is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The Company is committed to creating drugs for the better health of mankind. ENZCs flagship compound ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. IPF has not shown to be subject to viral resistance and is cost effective. Additional info from OTC: |